City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
Accepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
Accepting patients
CA088-1005
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 1
- Has results